Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II study of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

Summary

The purpose of this phase II study is to evaluate the safety and efficacy of Capecitabine and Temozolomide after surgery in patients with high-risk well- differentiated pancreatic neuroendocrine tumors.

General Information

NCT#: NCT05040360
Study ID: S2104
Trial Phase: Phase II

Trial Sponsor: Southwest Oncology Group (SWOG)
Therapies Used in This Trial: Capecitabine, Temozolomide

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search